Calithera Biosciences Inc represents a commitment to developing cutting-edge therapies in oncology and immuno-oncology. The company focuses on discovering and commercializing novel, small-molecule drugs that target tumor metabolism and the tumor microenvironment. By leveraging their scientific expertise, Calithera Biosciences aims to create innovative treatment options for cancer patients. With a dedication to scientific rigor and collaboration, they strive to improve patient outcomes and provide hope for those affected by cancer. Calithera Biosciences Inc believes in the power of science and innovation to make a meaningful impact in the fight against cancer.

Calithera Biosciences Inc primarily operates in the United States.

Calithera Biosciences Inc has achieved several significant milestones. The company has successfully developed a pipeline of novel cancer therapies and conducted clinical trials for various indications. It has obtained positive results in Phase I/II studies, showcasing the effectiveness and safety of its therapies. Calithera Biosciences has also secured strategic collaborations with renowned pharmaceutical companies, enabling further development and commercialization opportunities. The company's achievements demonstrate its commitment to advancing innovative treatments and addressing unmet medical needs in the field of oncology.

Calithera Biosciences Inc is a biopharmaceutical company focused on the discovery and development of novel small molecule drugs targeting tumor metabolism and tumor immunology. Founded in 2010, Calithera has successfully emerged as a leader in the field of cancer research. The company's extensive expertise and cutting-edge research have led to the development of innovative therapies that aim to improve the lives of patients with various types of cancer. Calithera Biosciences Inc has established collaborations with renowned academic institutions and industry partners to advance their pipeline of potential breakthrough treatments. With a strong commitment to scientific excellence, Calithera Biosciences Inc continues to strive towards transforming the landscape of cancer treatment.

The main competitors of Calithera Biosciences Inc in the market include companies such as Incyte Corporation, Exelixis Inc, and Blueprint Medicines Corporation. These companies also operate in the biopharmaceutical sector and focus on developing innovative therapies for the treatment of various diseases. However, Calithera Biosciences Inc sets itself apart through its unique therapeutic approaches, cutting-edge research, and strategic partnerships. By continuously advancing its pipeline and addressing unmet medical needs, Calithera Biosciences Inc aims to remain a competitive player in the biotech industry.

Calithera Biosciences Inc is primarily active in the biotechnology and pharmaceutical industries.

Calithera Biosciences Inc operates as a clinical-stage biopharmaceutical company. The company focuses on discovering and developing small molecule drugs targeting tumor and immune cell metabolism. It aims to develop therapies to treat patients with cancer by targeting the metabolic requirements of specific tumor and immune cell subsets. Calithera Biosciences Inc is committed to advancing its programs and exploring new therapeutic areas that have the potential to improve outcomes for patients.

De Calithera Biosciences K/W is -0,01.

De Calithera Biosciences KUV is 0.

De AlleAktien Kwaliteitsscore voor Calithera Biosciences is 3/10.

De omzet kan momenteel niet worden berekend voor Calithera Biosciences.

De verwachte Calithera Biosciences winst is -6,56 mln. USD.

Calithera Biosciences Inc is an emerging biopharmaceutical company specializing in the development of novel cancer therapies. The company's business model consists of three core areas: research and development, clinical trials, and marketing. In research and development, Calithera Biosciences focuses on identifying and developing therapies based on enzymes and metabolic processes. These approaches aim to disrupt cancer metabolism and thereby hinder or stop tumor growth. The company has several innovative products in the pipeline developed in this way. In the field of clinical trials, Calithera Biosciences collaborates closely with doctors and researchers at universities and hospitals. The company conducts clinical trials to demonstrate the effectiveness and safety of its therapies and to obtain the necessary regulatory approvals. This phase evaluates the potential of the products and, if necessary, improves them before they are later released for marketing. The marketing and sales of Calithera Biosciences' products are carried out through its sales and marketing division. The company has previously formed partnerships with major pharmaceutical and biotech companies to distribute and market its products. However, Calithera Biosciences also retains the possibility of successfully establishing its products in the market itself. One of the company's main products is CB-839, a selective inhibitor of glutamine metabolism used in cancer treatment. This product is currently in various stages of development and is being tested in clinical trials. It is characterized by high effectiveness and tolerability. Calithera Biosciences also plays an important role in preclinical research. The company continuously investigates new therapeutic approaches and identifies promising drug candidates that can be utilized by other individuals and companies through licensing agreements. In the past, the company has licensed its technology to other companies to increase its income. The company is also financially well-positioned and has sufficient resources to further develop its pipeline - the collection of drugs under development. It has successfully raised investments from venture capital investors as well as private and institutional investors in the past. Overall, Calithera Biosciences Inc has a promising business model focused on the development of novel cancer therapies. Its innovative research, close collaboration with other institutions, and excellent financing make the company an important player in the biopharmaceutical industry.

Calithera Biosciences keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Calithera Biosciences of het bedrijf keert geen dividend uit.

De ISIN van Calithera Biosciences is US13089P1012.

Het WKN van Calithera Biosciences is A12AQH.

De ticker van Calithera Biosciences is CALA.

Binnen de laatste 12 maanden betaalde Calithera Biosciences een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Calithera Biosciences naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Calithera Biosciences is momenteel .

Calithera Biosciences betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Calithera Biosciences betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Calithera Biosciences wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Calithera Biosciences van 3-8-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 3-8-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 3-8-2024.

In het jaar 2023 heeft Calithera Biosciences 0 USD aan dividenden uitgekeerd.

De dividenden van Calithera Biosciences worden in USD uitgekeerd.